6月4日，英矽智能盘中下跌5.21%，报38.68港元/股，成交额2187.28万港元。
消息面上，公司此前发布自愿公告，明确澄清目前尚无任何在阿布扎比进行第二上市的确切计划，市场此前预期该举措将拓展国际融资渠道并深化中东战略布局，预期落空持续压制投资者情绪。更为关键的是，公司去年12月登陆港股，当前已正式进入6月解禁窗口期，部分基石投资者及员工限售股面临到期，市场对潜在减持压力的担忧加剧抛售行为。据统计，近一个月公司股价累计跌幅已近40%。此外，生命科学工具和服务板块今日整体偏弱，药明生物跌0.31%，药明康德跌0.71%，金斯瑞生物科技跌2.38%，行业环境不佳进一步拖累表现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.